Table 1 Baseline characteristics of the populations studied.
From: Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis
Population 1 | Population 2 | Healthy donors | p | |
|---|---|---|---|---|
(n = 30) | (n = 32) | (n = 24) | ||
Female; n (%) | 25 (83.33) | 27 (84.38) | 20 (83.33) | 1 |
Age; p50 [p25–p75] | 52 [39–70] | 52 [43 – 60] | 52 [36–64] | 0.79 |
BMI; p50 [p25–p75] | 26.46 [23.5–29.27] | 26.78 [22.87–30.26] | 28.23 [25.05–29.37] | 0.646 |
RA/UA; n (%) | 30 (100)/0 (0) | 21 (65.63)/11 (34.38) | < 0.001 | |
Disease duration (months); p50 [p25–p75] | 6.48 [2.76–8.83] | 2.78 [2–7.81] | 0.060 | |
RF positive; n (%) | 22 (73.33) | 16(50) | 0.059 | |
ACPA positive; n (%) | 20(66.67) | 16(50) | 0.184 | |
DAS28; p50 [p25–p75] | 5.12 [3.89–5.8] | 3.91 [2.98–6.34] | 0.049 | |
HAQ; p50 [p25–p75] | 1.06 [0.62–1.62] | 1 [0.81–1.37] | 0.970 |
